June 21, 2017
Drugmaker Mylan gets boost from unlikely source: coal
Mylan N.V. <MYL.O> is best known for producing EpiPen emergency allergy treatments and generic drugs.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Regions
June 21, 2017
U.S. Supreme Court ruling threatens masive talc litigation against J&J
Johnson & Johnson is seizing upon a U.S. Supreme Court ruling from Monday limiting where injury lawsuits can be filed to fight off claims it failed to warn women that talcum powder could cause ovarian cancer.
June 20, 2017
Breast cancer patients testing Enzychem’s cheaper Mosedipimod, hopes for FDA’s approval
Announcing the phase 2 testing on Monday, the company said that the multicenter study of EC-18 (Mosedipimod), the world’s first oral medicine candidate to prevent and treat Chemotherapy-Induced Neutropenia (CIN), will begin dosing its first patient in the Asan Medical Center of Seoul, Korea. Enzychem also said it hopes to have EC-18 be approved by the FDA.
June 20, 2017
Sanovas expands in China, $75 million in capitalization
Sanovas, Inc., a Life Science technology company will establish a venture capital fund and Innovation Center at the Suzhou Institute of Nanotechnology and NanoBionics (SINANO) at the Chinese Academy of Sciences to advance the company’s innovations and sales in China.
June 20, 2017
Texas becoming big player in life science and biotech industry
Texas is headed to San Diego this week to showcase the state’s thriving biotechnology and life sciences sector at the world’s largest biotechnology conference, BIO International. More than 16,000 biotechnology and pharmaceutical leaders are expected to attend the annual conference, said Texas Economic Development Corporation.
June 19, 2017
New test may turn AZ’s Lynparza into precision drug for prostate cancer
Scientists have developed a new three-in-one blood test that has the potential to turn AstraZeneca’s drug Lynparza into a precision medicine for prostate cancer.
June 19, 2017
Health Canada approves Horizon Pharma’s nephropathic cystinosis drug
Health Canada has issued a Notice of Compliance (NOC) for Horizon Pharma’s Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children 2 years of age and older.
June 19, 2017
Novartis’s division wins EC approval for its cancer drug
European Commission (EC) has approved Sandoz’s Rixathon (biosimilar rituximab) for use in all indications of the reference medicine, MabThera.
June 14, 2017
Pfizer, Roche and Aspen face Shouth African probe into cancer drug prices
South Africa’s competition watchdog has launched an investigation into three drug companies accused of over-charging for cancer medicines, the agency’s chief said on Tuesday.
June 12, 2017
Sanofi’s and Regeneron’s diabetes drug testing shows positive results
Sanofi and Regeneron Pharmaceuticals have reported positive results from two Phase 3b/4 ODYSSEY-DM trials in patients with diabetes.